Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Change in Working Capital

Last Annual Value

306.24K

3-Year CAGR

-30%

5-Year CAGR

68%

10-Year CAGR

30%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Change in Working Capital

ANEB · NASDAQ
CompanyChange in Working Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
306.24K
-35.9%N/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
-3.35M
N/AN/AN/A
2.70M
17.8%N/AN/A
-9.12M
N/AN/AN/A
7.45M
-20.8%N/AN/A
-3.70M
N/AN/AN/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
380.17K
19.9%N/AN/A
-395.00K
N/AN/AN/A
-1.91M
N/AN/AN/A
-484.00K
N/AN/AN/A
-724.00K
N/AN/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72